Annual report
7747.TEDINET S100UFF7
Period2023-07-01 → 2024-06-30
Filed2024-09-27
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥107.5bn | 2023-07-01 → 2024-06-30 | Cons. | Net sales |
| Revenue | ¥90.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥77.7bn | 2021-07-01 → 2022-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥61.5bn | 2020-07-01 → 2021-06-30d | Cons. | Net sales (5-year summary) |
| Revenue | ¥56.5bn | 2019-07-01 → 2020-06-30d | Cons. | Net sales (5-year summary) |
| Operating income | ¥22.1bn | 2023-07-01 → 2024-06-30 | Cons. | Operating income |
| Operating income | ¥18.0bn | 2022-07-01 → 2023-06-30 | Cons. | Operating income |
| Ordinary income | ¥22.0bn | 2023-07-01 → 2024-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥17.6bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥16.3bn | 2021-07-01 → 2022-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.2bn | 2020-07-01 → 2021-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.3bn | 2019-07-01 → 2020-06-30d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥21.8bn | 2023-07-01 → 2024-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥17.7bn | 2022-07-01 → 2023-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥15.8bn | 2023-07-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.1bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥10.9bn | 2021-07-01 → 2022-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥10.0bn | 2020-07-01 → 2021-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.2bn | 2019-07-01 → 2020-06-30d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥15.9bn | 2023-07-01 → 2024-06-30 | Cons. | Profit loss |
| Net income | ¥13.3bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss |
| Total assets | ¥191.6bn | at 2024-06-30 | Cons. | Assets |
| Total assets | ¥172.6bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥155.1bn | at 2022-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥115.4bn | at 2021-06-30d | Cons. | Total assets (5-year summary) |
| Total assets | ¥93.7bn | at 2020-06-30d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥39.7bn | at 2024-06-30 | Cons. | Liabilities |
| Total liabilities | ¥38.3bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥152.0bn | at 2024-06-30 | Cons. | Net assets |
| Net assets / equity | ¥134.3bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥121.1bn | at 2022-06-30d | Cons. | Net assets |
| Net assets / equity | ¥92.9bn | at 2021-06-30d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥72.0bn | at 2020-06-30d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥35.7bn | at 2024-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥34.9bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥35.7bn | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥34.9bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥32.3bn | at 2022-06-30d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.4bn | at 2021-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥18.6bn | at 2020-06-30d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥34.7bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥19.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥17.3bn | 2021-07-01 → 2022-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.9bn | 2020-07-01 → 2021-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥11.2bn | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥21.2bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥15.1bn | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥18.7bn | 2021-07-01 → 2022-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥16.3bn | 2020-07-01 → 2021-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥10.4bn | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥13.9bn | 2023-07-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.3bn | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥11.4bn | 2021-07-01 → 2022-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥10.1bn | 2020-07-01 → 2021-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥850m | 2019-07-01 → 2020-06-30d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥58.2 | 2023-07-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.25 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.01 | 2021-07-01 → 2022-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.25 | 2020-07-01 → 2021-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.25 | 2019-07-01 → 2020-06-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥40 | 2021-07-01 → 2022-06-30d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥38.07 | 2020-07-01 → 2021-06-30d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥35.07 | 2019-07-01 → 2020-06-30d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥556.71 | at 2024-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥487.12 | at 2023-06-30 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥439.8 | at 2022-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥349.18 | at 2021-06-30d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥276.13 | at 2020-06-30d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 78.9% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.6% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 77.0% | at 2022-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.5% | at 2021-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.8% | at 2020-06-30d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 11.2% | 2023-07-01 → 2024-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.4% | 2022-07-01 → 2023-06-30 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2021-07-01 → 2022-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 12.1% | 2020-07-01 → 2021-06-30d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 13.4% | 2019-07-01 → 2020-06-30d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 9,371 | at 2024-06-30 | Cons. | Number of employees |
| Employees | 10,187 | at 2023-06-30 | Cons. | Number of employees |
| Employees | 10,435 | at 2022-06-30d | Cons. | Number of employees |
| Employees | 9,409 | at 2021-06-30d | Cons. | Number of employees |
| Employees | 8,761 | at 2020-06-30d | Cons. | Number of employees |
| Revenue | ¥73.8bn | 2023-07-01 → 2024-06-30 | Standalone | Net sales |
| Revenue | ¥63.7bn | 2022-07-01 → 2023-06-30 | Standalone | Net sales |
| Revenue | ¥63.5bn | 2021-07-01 → 2022-06-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥50.9bn | 2020-07-01 → 2021-06-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥47.4bn | 2019-07-01 → 2020-06-30d | Standalone | Net sales (5-year summary) |
| Operating income | ¥13.8bn | 2023-07-01 → 2024-06-30 | Standalone | Operating income |
| Operating income | ¥12.3bn | 2022-07-01 → 2023-06-30 | Standalone | Operating income |
| Ordinary income | ¥13.9bn | 2023-07-01 → 2024-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥12.3bn | 2022-07-01 → 2023-06-30 | Standalone | Ordinary income |
| Ordinary income | ¥13.2bn | 2021-07-01 → 2022-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.9bn | 2020-07-01 → 2021-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥10.0bn | 2019-07-01 → 2020-06-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥13.7bn | 2023-07-01 → 2024-06-30 | Standalone | Income before income taxes |
| Profit before tax | ¥10.1bn | 2022-07-01 → 2023-06-30 | Standalone | Income before income taxes |
| Net income | ¥10.9bn | 2023-07-01 → 2024-06-30 | Standalone | Profit loss |
| Net income | ¥7.2bn | 2022-07-01 → 2023-06-30 | Standalone | Profit loss |
| Net income | ¥9.5bn | 2021-07-01 → 2022-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥6.7bn | 2020-07-01 → 2021-06-30d | Standalone | Net income loss (5-year summary) |
| Net income | ¥7.9bn | 2019-07-01 → 2020-06-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥139.1bn | at 2024-06-30 | Standalone | Assets |
| Total assets | ¥127.3bn | at 2023-06-30 | Standalone | Assets |
| Total assets | ¥120.9bn | at 2022-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥91.4bn | at 2021-06-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥71.3bn | at 2020-06-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥41.3bn | at 2024-06-30 | Standalone | Liabilities |
| Total liabilities | ¥37.1bn | at 2023-06-30 | Standalone | Liabilities |
| Net assets / equity | ¥97.8bn | at 2024-06-30 | Standalone | Net assets |
| Net assets / equity | ¥90.2bn | at 2023-06-30 | Standalone | Net assets |
| Net assets / equity | ¥86.2bn | at 2022-06-30d | Standalone | Net assets |
| Net assets / equity | ¥67.2bn | at 2021-06-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥49.6bn | at 2020-06-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥16.7bn | at 2024-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥25.4bn | at 2023-06-30 | Standalone | Cash and deposits |
| EPS (basic) | ¥40.11 | 2023-07-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥26.61 | 2022-07-01 → 2023-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥35.09 | 2021-07-01 → 2022-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥25.8 | 2020-07-01 → 2021-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥30.32 | 2019-07-01 → 2020-06-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥35.08 | 2021-07-01 → 2022-06-30d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥25.68 | 2020-07-01 → 2021-06-30d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥30.16 | 2019-07-01 → 2020-06-30d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥20.37 | 2023-07-01 → 2024-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14.48 | 2022-07-01 → 2023-06-30 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11.99 | 2021-07-01 → 2022-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥11.26 | 2020-07-01 → 2021-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥8.81 | 2019-07-01 → 2020-06-30d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥360.2 | at 2024-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥332.15 | at 2023-06-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥317.39 | at 2022-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥252.48 | at 2021-06-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥190.43 | at 2020-06-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 70.3% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.9% | at 2023-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.3% | at 2022-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.4% | at 2021-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.6% | at 2020-06-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 11.6% | 2023-07-01 → 2024-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2022-07-01 → 2023-06-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 12.4% | 2021-07-01 → 2022-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.5% | 2020-07-01 → 2021-06-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.8% | 2019-07-01 → 2020-06-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 271,633,600 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 271,633,600 | at 2023-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 271,633,600 | at 2022-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 265,972,800 | at 2021-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 260,561,600 | at 2020-06-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 1,088 | at 2024-06-30 | Standalone | Number of employees |
| Employees | 1,016 | at 2023-06-30 | Standalone | Number of employees |
| Employees | 1,041 | at 2022-06-30d | Standalone | Number of employees |
| Employees | 925 | at 2021-06-30d | Standalone | Number of employees |
| Employees | 875 | at 2020-06-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 56
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-07-01 → 2024-06-30 | ¥904m |
| Reconciling Itemsreconciling | depreciation | 2023-07-01 → 2024-06-30 | ¥329m |
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2024-06-30 | −¥14.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2024-06-30 | −¥14.3bn |
| Reconciling Itemsreconciling | segment assets | at 2024-06-30 | ¥28.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2024-06-30 | −¥5.3bn |
| Devicereportable segment | capex | 2023-07-01 → 2024-06-30 | ¥5.6bn |
| Devicereportable segment | depreciation | 2023-07-01 → 2024-06-30 | ¥3.3bn |
| Devicereportable segment | employees | at 2024-06-30 | 3062 pure |
| Devicereportable segment | revenue | 2023-07-01 → 2024-06-30 | ¥26.1bn |
| Devicereportable segment | revenue external | 2023-07-01 → 2024-06-30 | ¥11.9bn |
| Devicereportable segment | revenue intersegment | 2023-07-01 → 2024-06-30 | ¥14.3bn |
| Devicereportable segment | segment assets | at 2024-06-30 | ¥46.1bn |
| Devicereportable segment | segment profit | 2023-07-01 → 2024-06-30 | ¥4.7bn |
| Medicalreportable segment | capex | 2023-07-01 → 2024-06-30 | ¥6.1bn |
| Medicalreportable segment | depreciation | 2023-07-01 → 2024-06-30 | ¥4.8bn |
| Medicalreportable segment | employees | at 2024-06-30 | 5773 pure |
| Medicalreportable segment | revenue | 2023-07-01 → 2024-06-30 | ¥95.7bn |
| Medicalreportable segment | revenue external | 2023-07-01 → 2024-06-30 | ¥95.7bn |
| Medicalreportable segment | segment assets | at 2024-06-30 | ¥117.2bn |
| Medicalreportable segment | segment profit | 2023-07-01 → 2024-06-30 | ¥22.7bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-07-01 → 2024-06-30 | ¥11.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-07-01 → 2024-06-30 | ¥8.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-07-01 → 2024-06-30 | ¥121.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-07-01 → 2024-06-30 | ¥107.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-07-01 → 2024-06-30 | ¥14.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-06-30 | ¥163.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-07-01 → 2024-06-30 | ¥27.4bn |
| Reconciling Itemsreconciling | capex | 2022-07-01 → 2023-06-30 | ¥315m |
| Reconciling Itemsreconciling | depreciation | 2022-07-01 → 2023-06-30 | ¥295m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2023-06-30 | −¥14.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2023-06-30 | −¥14.5bn |
| Reconciling Itemsreconciling | segment assets | at 2023-06-30 | ¥17.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2023-06-30 | −¥4.5bn |
| Devicereportable segment | capex | 2022-07-01 → 2023-06-30 | ¥6.3bn |
| Devicereportable segment | depreciation | 2022-07-01 → 2023-06-30 | ¥2.9bn |
| Devicereportable segment | revenue | 2022-07-01 → 2023-06-30 | ¥26.0bn |
| Devicereportable segment | revenue external | 2022-07-01 → 2023-06-30 | ¥11.5bn |
| Devicereportable segment | revenue intersegment | 2022-07-01 → 2023-06-30 | ¥14.5bn |
| Devicereportable segment | segment assets | at 2023-06-30 | ¥39.3bn |
| Devicereportable segment | segment profit | 2022-07-01 → 2023-06-30 | ¥6.1bn |
| Medicalreportable segment | capex | 2022-07-01 → 2023-06-30 | ¥7.8bn |
| Medicalreportable segment | depreciation | 2022-07-01 → 2023-06-30 | ¥4.3bn |
| Medicalreportable segment | revenue | 2022-07-01 → 2023-06-30 | ¥78.6bn |
| Medicalreportable segment | revenue external | 2022-07-01 → 2023-06-30 | ¥78.6bn |
| Medicalreportable segment | segment assets | at 2023-06-30 | ¥115.6bn |
| Medicalreportable segment | segment profit | 2022-07-01 → 2023-06-30 | ¥16.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-07-01 → 2023-06-30 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-07-01 → 2023-06-30 | ¥7.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-07-01 → 2023-06-30 | ¥104.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-07-01 → 2023-06-30 | ¥90.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-07-01 → 2023-06-30 | ¥14.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-06-30 | ¥154.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-07-01 → 2023-06-30 | ¥22.5bn |
| Devicereportable segment | employees | at 2024-06-30 | 314 pure |
| Medicalreportable segment | employees | at 2024-06-30 | 646 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,585
| Item | Context | Value | Unit |
|---|---|---|---|
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000TomidaRyujiMember | Original text (Japanese)取締役(監査等委員である取締役) | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000TomidaRyujiMember | Original text (Japanese)富田 隆司 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000TomidaRyujiMember | 1975-04-03 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E02349-000TomidaRyujiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000TomidaRyujiMember | Original text (Japanese)注５ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000FukayaRyoukoMember | Original text (Japanese)取締役(監査等委員である取締役) | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000FukayaRyoukoMember | Original text (Japanese)深谷 玲子 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000FukayaRyoukoMember | 1973-05-12 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E02349-000FukayaRyoukoMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000FukayaRyoukoMember | Original text (Japanese)注５ | |
| Official title or position information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000MorigutiSigekiMember | Original text (Japanese)取締役(監査等委員である取締役) | |
| Name information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000MorigutiSigekiMember | Original text (Japanese)森口 茂樹 | |
| Date of birth information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000MorigutiSigekiMember | 1957-07-23 | |
| Career summary information about directors and corporate auditors (text) | FilingDateInstant_jpcrp030000-asr_E02349-000MorigutiSigekiMember | Text · Plus | |
| Term of office information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02349-000MorigutiSigekiMember | Original text (Japanese)注５ | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row2Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row3Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row4Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row5Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row6Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row7Member | Text · Plus | |
| Footnotes directors and corporate auditors (text) | FilingDateInstant_Row8Member | Text · Plus | |
| Outside directors and outside corporate auditors (text) | FilingDateInstant | Text · Plus | |
| Audits (text) | FilingDateInstant | Text · Plus | |
| Remuneration for directors and other officers (text) | FilingDateInstant | Text · Plus | |
| Remuneration etc paid by group to each director or other officer (text) | FilingDateInstant | Text · Plus | |
| Shareholdings (text) | FilingDateInstant | Text · Plus | |
| Reason for increase in number of shares shares not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | Original text (Japanese)事業強化 | |
| Reason for increase in number of shares shares other than those not listed investment shares held for purposes other than pure investment reporting company | CurrentYearDuration | Original text (Japanese)子会社（トヨフレックス株式会社）の吸収合併 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)㈱ホギメディカル | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row1Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)グローブライド㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row2Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | ㈱FUJI | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)（保有目的）技術・研究開発における協力関係の維持・強化（業務提携等の概要） 医療機器の開発 （定量的な保有効果）（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row3Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)オリンパス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)（保有目的）安定的な営業取引関係の維持・強化 （定量的な保有効果）（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)オンコリスバイオファーマ㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)（保有目的）新規事業強化 （定量的な保有効果）（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)クオリプス㈱ | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)（保有目的）技術・研究開発における協力関係の維持・強化（業務提携等の概要）新規デバイスの開発（定量的な保有効果）（注） | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)無 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |